DTC
Deep Track Capital Portfolio holdings
AUM
$3.11B
This Quarter Return
+23.38%
1 Year Return
+13.6%
3 Year Return
+265.73%
5 Year Return
–
10 Year Return
–
AUM
$3.48B
AUM Growth
+$3.48B
(+22%)
Cap. Flow
+$477M
Cap. Flow
% of AUM
13.71%
Top 10 Holdings %
Top 10 Hldgs %
38.49%
Holding
77
New
19
Increased
14
Reduced
16
Closed
11
Top Buys
| 1 |
Amgen
AMGN
|
$156M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$124M |
| 3 |
Dyne Therapeutics
DYN
|
$72.5M |
| 4 |
MindMed
MNMD
|
$62.7M |
| 5 |
Apellis Pharmaceuticals
APLS
|
$58.8M |
Top Sells
| 1 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$52.8M |
| 2 |
Sarepta Therapeutics
SRPT
|
$48.2M |
| 3 |
RAPT Therapeutics
RAPT
|
$44.6M |
| 4 |
Arcellx
ACLX
|
$40.2M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
$34.6M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
SWTX
1
DELISTED
SpringWorks Therapeutics
SWTX
| $171M | 4.91% | 3,479,853 -583,823 | -14% | -$28.7M |
|
|
2
Amgen
AMGN
$155B
| $156M | 4.48% | +550,000 | New | +$156M |
|
3
Apogee Therapeutics
APGE
$2.17B
| $154M | 4.42% | 2,323,456 | – | – |
|
4
Insmed
INSM
$28.8B
| $130M | 3.72% | 4,783,679 -566,321 | -11% | -$15.4M |
|
|
5
Dyne Therapeutics
DYN
$1.92B
| $129M | 3.7% | 4,555,383 +2,555,383 | +128% | +$72.5M |
|
|
6
Alnylam Pharmaceuticals
ALNY
$58.5B
| $124M | 3.56% | +832,310 | New | +$124M |
|
7
Guardant Health
GH
$8.41B
| $124M | 3.55% | 6,000,000 +1,000,000 | +20% | +$20.6M |
|
8
argenx
ARGX
$43.6B
| $118M | 3.38% | 300,000 | – | – |
|
9
Intellia Therapeutics
NTLA
$1.22B
| $116M | 3.32% | 4,210,784 +1,960,784 | +87% | +$53.9M |
|
10
Ocular Therapeutix
OCUL
$2.12B
| $116M | 3.32% | 12,721,460 +3,490,691 | +38% | +$31.8M |
|
11
Dynavax Technologies
DVAX
$1.19B
| $113M | 3.25% | 9,141,660 +2,048,446 | +29% | +$25.4M |
|
12
Axsome Therapeutics
AXSM
$6.05B
| $104M | 2.98% | 1,304,721 +304,721 | +30% | +$24.3M |
|
|
ITCI
13
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $104M | 2.97% | 1,500,000 -500,000 | -25% | -$34.6M |
|
14
Geron
GERN
$893M
| $101M | 2.88% | 30,505,929 +922,480 | +3% | +$3.04M |
|
|
AUTL
15
Autolus Therapeutics
AUTL
$399M
| $97.4M | 2.79% | 15,272,172 +3,402,875 | +29% | +$21.7M |
|
16
4D Molecular Therapeutics
FDMT
$288M
| $96.7M | 2.77% | 3,034,453 +750,081 | +33% | +$23.9M |
|
17
Alkermes
ALKS
$4.78B
| $94.7M | 2.71% | 3,500,000 -500,000 | -13% | -$13.5M |
|
|
BCYC
18
Bicycle Therapeutics
BCYC
$511M
| $86.9M | 2.49% | 3,490,506 | – | – |
|
19
Pliant Therapeutics
PLRX
$101M
| $85.7M | 2.45% | 5,750,000 | – | – |
|
|
20
MindMed
MNMD
$676M
| $62.7M | 1.8% | +6,666,667 | New | +$62.7M |
|
|
ABVX
21
Abivax
ABVX
$6.12B
| $61.5M | 1.76% | 4,297,438 | – | – |
|
22
Viridian Therapeutics
VRDN
$1.5B
| $60.5M | 1.73% | 3,456,053 -175,675 | -5% | -$3.08M |
|
23
Ionis Pharmaceuticals
IONS
$6.8B
| $59.5M | 1.71% | 1,373,475 +124,407 | +10% | +$5.39M |
|
|
24
Apellis Pharmaceuticals
APLS
$3.48B
| $58.8M | 1.68% | +1,000,000 | New | +$58.8M |
|
25
ANI Pharmaceuticals
ANIP
$2.03B
| $56.8M | 1.63% | 822,001 +222,001 | +37% | +$15.3M |
|